Renal Cancer - Results from #1960

LRRK2 is a candidate prognostic biomarker for clear cell renal cell carcinoma. July 8, 2021

Outcome of immune checkpoint inhibitors in metastatic renal cell carcinoma across different treatment lines. July 7, 2021

Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade. July 7, 2021

Outcomes of renal cell carcinoma with associated venous tumor thrombus: experience from a large cohort and short time span in a single center. July 6, 2021

Stereotactic Body Radiotherapy for Frail Patients with Primary Renal Cell Carcinoma: Preliminary Results after 4 Years of Experience. July 6, 2021

Integration of NRP1, RGS5, and FOXM1 expression, and tumour necrosis, as a postoperative prognostic classifier based on molecular subtypes of clear cell renal cell carcinoma. July 5, 2021

Deciphering Intratumoral Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma with a Radiogenomics Platform. July 5, 2021

Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy? July 2, 2021

The increasing use of renal tumor biopsy amongst Canadian urologists: When is biopsy most utilized? July 2, 2021

Does a Positive Surgical Margin after Nephron Sparing Surgery Affect Oncological Outcome in Renal Cell Carcinoma? A Systematic Review and Meta-Analysis. July 1, 2021

Integrated transcriptional-phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients. July 1, 2021

Prognostic Significance of Pancreatic Metastases in Patients With Advanced Renal Cell Carcinoma Treated With Systemic Therapy. June 30, 2021

A deep-learning based artificial intelligence (AI) approach for differentiation of clear cell renal cell carcinoma from oncocytoma on multi-phasic MRI. June 30, 2021

Effects of early vs delayed progression on clinical and economic outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors as first-line therapy: results from the IMPACT RCC claims data analysis. June 29, 2021

Oncological Outcomes of Patients With Different Pathological Features of pT3a Renal Tumor: A Systematic Review and Quantitative Synthesis. June 29, 2021

Immune-related adverse events as clinical biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors. June 28, 2021

Comparison of Perioperative Outcomes for Radical Nephrectomy Based on Surgical Approach for Masses Greater than 10cm. June 28, 2021

Machine Learning-Enabled Renal Cell Carcinoma Status Prediction Using Multiplatform Urine-Based Metabolomics. June 25, 2021

Active Surveillance in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System. June 25, 2021

Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden. June 24, 2021

Page 99 of 456